Lumos Net Income vs Capital Expenditures Analysis
| LUMO Stock | USD 4.34 0.01 0.23% |
Lumos Pharma financial indicator trend analysis is infinitely more than just investigating Lumos Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lumos Pharma is a good investment. Please check the relationship between Lumos Pharma Net Income and its Capital Expenditures accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.
Net Income vs Capital Expenditures
Net Income vs Capital Expenditures Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lumos Pharma Net Income account and Capital Expenditures. At this time, the significance of the direction appears to have no relationship.
The correlation between Lumos Pharma's Net Income and Capital Expenditures is 0.07. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Lumos Pharma, assuming nothing else is changed. The correlation between historical values of Lumos Pharma's Net Income and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Lumos Pharma are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Net Income i.e., Lumos Pharma's Net Income and Capital Expenditures go up and down completely randomly.
Correlation Coefficient | 0.07 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Lumos Pharma financial statement analysis. It represents the amount of money remaining after all of Lumos Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Capital Expenditures
Capital Expenditures are funds used by Lumos Pharma to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Lumos Pharma operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most indicators from Lumos Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lumos Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.At this time, Lumos Pharma's Selling General Administrative is very stable compared to the past year. As of the 16th of December 2024, Issuance Of Capital Stock is likely to grow to about 761.2 K, while Tax Provision is likely to drop (44.1 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 484K | 874K | 1.0M | 671.3K | Depreciation And Amortization | 203K | 49K | 44K | 41.8K |
Lumos Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Lumos Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lumos Pharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 96.8M | 129.0M | 100.3M | 72.3M | 40.6M | 38.6M | |
| Short Long Term Debt Total | 1.2M | 319K | 557K | 233K | 585K | 555.8K | |
| Other Current Liab | 10.2M | 5.6M | 3.8M | 6.0M | 5.6M | 5.8M | |
| Total Current Liabilities | 11.8M | 6.5M | 5.1M | 6.7M | 7.0M | 11.8M | |
| Total Stockholder Equity | 78.9M | 116.6M | 89.0M | 59.6M | 27.3M | 25.9M | |
| Property Plant And Equipment Net | 2.4M | 584K | 635K | 283K | 603K | 572.9K | |
| Net Debt | (89.3M) | (98.4M) | (94.3M) | (55.8M) | (34.5M) | (36.2M) | |
| Retained Earnings | (334.0M) | (66.0M) | (96.4M) | (127.5M) | (161.5M) | (169.6M) | |
| Accounts Payable | 475K | 244K | 612K | 275K | 890K | 845.5K | |
| Cash | 90.5M | 98.7M | 94.8M | 56.0M | 35.1M | 33.3M | |
| Non Current Assets Total | 2.4M | 584K | 635K | 283K | 603K | 572.9K | |
| Non Currrent Assets Other | 735K | (584K) | (635K) | (283K) | (325.5K) | (341.7K) | |
| Cash And Short Term Investments | 90.5M | 98.7M | 94.8M | 67.4M | 36.1M | 34.3M | |
| Net Receivables | 824K | 26.3M | 128K | 223K | 210K | 199.5K | |
| Common Stock Total Equity | 372K | 373K | 12K | 83K | 74.7K | 71.0K | |
| Common Stock Shares Outstanding | 144.7K | 6.8M | 8.3M | 8.4M | 8.1M | 4.1M | |
| Liabilities And Stockholders Equity | 96.8M | 129.0M | 100.3M | 72.3M | 40.6M | 38.6M | |
| Non Current Liabilities Total | 6.9M | 6.1M | 6M | 6.2M | 6.3M | 6.0M | |
| Other Current Assets | 3.0M | 3.5M | 4.7M | 4.4M | 3.7M | 6.2M | |
| Other Stockholder Equity | 412.5M | 311.5M | 185.3M | 187.0M | 188.7M | 223.2M | |
| Total Liab | 17.9M | 12.5M | 11.3M | 12.7M | 13.3M | 21.4M | |
| Property Plant And Equipment Gross | 457K | 584K | 635K | 283K | 603K | 572.9K | |
| Total Current Assets | 94.4M | 128.4M | 99.7M | 72.0M | 40.0M | 38.0M | |
| Accumulated Other Comprehensive Income | (6.6M) | (7.0M) | (63.5M) | (129.0M) | 0.0 | (9K) | |
| Short Term Debt | 1.1M | 638K | 704K | 466K | 564K | 579.2K | |
| Common Stock | 373K | 374K | 83K | 82K | 81K | 77.0K | |
| Net Tangible Assets | 78.9M | 116.6M | 89.0M | 59.6M | 68.5M | 104.9M | |
| Retained Earnings Total Equity | (237.5M) | (291.0M) | (334.0M) | (66.0M) | (59.4M) | (62.4M) | |
| Capital Surpluse | 389.8M | 407.2M | 414.0M | 182.5M | 209.9M | 293.4M | |
| Property Plant Equipment | 1.6M | 335K | 635K | 283K | 254.7K | 242.0K |
Pair Trading with Lumos Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lumos Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lumos Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Lumos Stock
| 0.81 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.8 | LLY | Eli Lilly | PairCorr |
| 0.75 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.7 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.64 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Lumos Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lumos Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lumos Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lumos Pharma to buy it.
The correlation of Lumos Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lumos Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lumos Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lumos Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.